All Stories

  1. Recent advances in understanding and managing hepatic encephalopathy in chronic liver disease
  2. Novel therapies in the management of acute episodes of hepatic encephalopathy
  3. Acute-on-Chronic Liver Failure: A Distinct Clinical Condition
  4. From the Editor’s desk...
  5. From the Editor’s desk...
  6. From the Editor’s desk…
  7. Hepatic encephalopathy: New treatments
  8. Emerging trends in hepatology: 30years of the Journal of Hepatology and 50years of EASL
  9. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis
  10. Acute-on-Chronic Liver Failure: Recent Concepts
  11. Attenuation of Congenital Portosystemic Shunt Reduces Inflammation in Dogs
  12. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure
  13. A Multi-Journal Partnership to Highlight Joint First-Authors of Manuscripts
  14. A Multi-Journal Partnership to Highlight Joint First-Authors of Manuscripts
  15. A multi-journal partnership to highlight joint first-authors of manuscripts
  16. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension
  17. Acute-on-chronic liver failure
  18. A multi-journal partnership to highlight joint first-authors of manuscripts
  19. A multi-journal partnership to highlight joint first-authors of manuscripts
  20. Liver Support Systems
  21. Journal of Hepatology: The home of liver research
  22. L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway
  23. Novel insights into ammonia-mediated neurotoxicity pointing to potential new therapeutic strategies
  24. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma
  25. Pharmacotherapy for hyperammonemia
  26. Inflammation and portal hypertension – The undiscovered country
  27. ‘Hepatology’ on the move
  28. Joan Cordoba Cordona (1964–2014): A dedicated clinician, great scientist, mentor, friend, collaborator, critic…
  29. The brain in acute on chronic liver failure
  30. Obeticholic acid, a Farensoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
  31. Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure
  32. P105 ACTIVATION OF SENESCENT GENES IN CHRONIC AND ACUTE-ON-CHRONIC LIVER FAILURE RAT BRAINS
  33. P39 EVIDENCE THAT AMMONIA ACTS AS A DANGER ASSOCIATED MOLECULAR PATTERN (DAMP) AND SIGNALS THROUGH THE TOLL-LIKE RECEPTOR-4 (TLR4) PATHWAY
  34. P24 L-ORNITHINE PHENYLACETATE REDUCES AMMONIA IN PIGS WITH ACUTE LIVER FAILURE THROUGH PHENYLACETYLGLYCINE FORMATION: A NOVEL AMMONIA-LOWERING PATHWAY
  35. P28 EVIDENCE FOR INTRACELLULAR IMMUNOMODULATORY AND ANTIOXIDANT ACTION OF ALBUMIN TO PROVIDE ENDOTHELIAL PROTECTION IN LIVER FAILURE
  36. O15 EFFECTS OF THE FXR AGONIST OBETICHOLIC ACID ON HEPATIC VENOUS PRESSURE GRADIENT (HVPG) IN ALCOHOLIC CIRRHOSIS: A PROOF OF CONCEPT PHASE 2A STUDY
  37. O70 LIFETOUCH: A NOVEL REMOTE MONITORING DEVICE TO IDENTIFY PATIENTS WITH ADVANCED CIRRHOSIS MOST AT RISK OF DECOMPENSATION – A PROOF OF CONCEPT STUDY
  38. P91 EFFECT OF TOLL-LIKE RECEPTOR 7 AND 9 TARGETED THERAPY TO PREVENT THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA
  39. P340 ALBUMIN EXCHANGE AND ENDOTOXIN REMOVAL USING THE NOVEL UCL-LIVER DIALYSIS DEVICE (UCL-LDD) PROLONGS SURVIVAL IN ACETAMINOPHEN-INDUCED ACUTE LIVER FAILURE (ALF)
  40. P36 ADMINISTRATION OF RECOMBINANT ALKALINE PHOSPHATASE PREVENTS DEVELOPMENT OF ACUTE ON CHRONIC LIVER FAILURE (ACLF) IN A RODENT BILE-DUCT LIGATION MODEL
  41. P949 QUANTITATION AND LOCATION OF THE SEVERITY OF BRAIN EDEMA IN PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE AND HEPATIC ENCEPHALOPATHY
  42. Brain lactate in hepatic encephalopathy: Friend or foe?
  43. L-Ornithine Phenylacetate (OCR-002) Ameliorates Portal Hypertension by Modulating NFKB Driven Inflammatory Pathway in Cirrhosis
  44. Arterial ammonia levels in cirrhosis are determined by systemic and hepatic hemodynamics, and by organ function: a quantitative modelling study
  45. Effective albumin concentration and cirrhosis mortality: From concept to reality
  46. Treatment of hyperammonemia in liver failure
  47. Hemostasis in patients with acute kidney injury secondary to acute liver failure
  48. Reply to: “Acute-on-chronic liver failure – Its definition remains unclear”
  49. Role of Toll-Like Receptor 4 in Mediating Multiorgan Dysfunction in Mice With Acetaminophen Induced Acute Liver Failure
  50. Cracking the ENCODE: From transcription to therapeutics
  51. When to use renal replacement therapy and bioartificial support for renal failure in patients with cirrhosis
  52. Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications
  53. Beyond scoring: a modern interpretation of disease progression in chronic liver disease
  54. 571 P2X7 RECEPTOR IN ACUTE KIDNEY INJURY OF CIRRHOSIS: A POTENTIAL NOVEL TARGET OF THERAPY
  55. 578 ALBUMIN INFUSION IMPROVES SYSTEMIC AND RENAL BLOOD FLOW AUTOREGULATION BY RESTORATION OF ENDOTHELIAL DYSFUNCTION
  56. 1064 TARGETING TLR7 AND 9: A NOVEL STRATEGY FOR TREATMENT OF CHOLANGIOCARCINOMA
  57. 77 EMBOLIZATION OF LARGE SPONTANEOUS PORTOSYSTEMIC SHUNTS FOR REFRACTORY HEPATIC ENCEPHALOPATHY: A EUROPEAN MULTI-CENTER SURVEY ON SAFETY & EFFICACY
  58. 534 MUSCLE GLUTAMINE SYNTHASE REGULATES THE SEVERITY OF HYPERAMMONEMIA, HEPATIC INFLAMMATION, BRAIN SWELLING AND SURVIVAL IN ACETAMINOPHEN HEPATOTOXICITY
  59. Ornithine phenylacetate revisited
  60. Activation of farnesoid X receptor (FXR) by its agonist int-747 restores hepatic endothelial NOS activity and lowers portal pressure in cirrhotic rats by modulating the DDAH-ADMA pathway
  61. An exciting time for Hepatology
  62. Acute-on chronic liver failure
  63. Evaluation of coagulation abnormalities in acute liver failure
  64. Reply to: “Is a liver biopsy necessary in alcoholic hepatitis?”
  65. Neurological complications of acute liver failure: Pathophysiological basis of current management and emerging therapies
  66. PTU-010 Computational model predicts that portosystemic shunting is key to the development of hyperammonaemia in liver cirrhosis
  67. OC-068 Albumin is central in mediating the cardio-renal dysfunction of cirrhosis: a study in analbuminaemic rats: Abstract OC-068 Figure 1
  68. PTU-016 Albumin restores renal blood flow (RBF) autoregulation in patients with refractory ascites and acute-on-chronic liver failure (ACLF) through stabilisation of endothelial function: Abstract PTU-016 Figure 1
  69. PMO-128 Effects of oral nanoporous carbon therapy in leptin null mice as a model of non-alcoholic steatohepatitis
  70. PMO-127 Biological effects of oral nanoporous carbon in bile duct ligated rats
  71. PTU-008 A reproducible, clinically-relevant, intensively-managed, pig model of acute liver failure for testing of therapies aimed to prolong survival
  72. PMO-142 Evidence refuting the Trojan-horse hypothesis of brain swelling in acute liver failure: l-type glutaminase is exclusively neuronal: Abstract PMO-142 Figure 1
  73. PTU-049 Modulation of toll-like receptor genes with selective gut decontamination in cirrhotic animals prevents the development of acute-on chronic liver failure (ACLF)
  74. PWE-264 Blood lipidomic profiling of hepatocellular carcinoma in human and animal studies identifies lysophosphatidylcholine (24, 0, 0), a discriminatory biomarker
  75. PWE-265 Plasma metabolite profiling in a rat model of hepatocellular carcinoma and the effects of co-administered antibiotics
  76. PWE-267 Urinary TLR4: a novel biomarker to identify patients with acute kidney injury in patients with acute on chronic liver failure: Abstract PWE-267 Figure 1
  77. OC-023 Extracorporeal liver support using UCL-arsenel reduces inflammation, improves haemodynamic function and increase survival time in a porcine paracetamol-induced acute liver failure model
  78. PMO-092 TLR7 expression is increased in hepatocellular cancer (HCC) and its modulation is associated with alterations in tumour growth: a novel therapeutic target
  79. PMO-091 TLR 9 inhibition: a novel target of therapy for primary liver cancer
  80. PTU-030 Selective gut decomtamination reduces hepatic expression of toll-like receptor (TLR) 4 and development of cirrhosis but does not prevent development of hepatocellular carcinoma (HCC)
  81. PMO-123 Gene transfer of dimethylarginine dimethylaminohydrolase-1 reduces portal pressure in a rodent model of cirrhosis
  82. OC-066 Toll like receptor 4 antagonist prevents acetaminophen induced acute liver failure in mice: a novel therapeutic strategy
  83. Reply to: “The quest for the elusive factors that underpin neutrophil dysfunction in cirrhosis goes on”
  84. Mechanistic biomarkers in acute liver injury: Are we there yet?
  85. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression
  86. 597 PERICYTE ACTIVATION AND CEREBRAL SEQULAE OF CIRRHOSIS
  87. Albumin Regeneration for Extracorporeal Liver Support Using Prometheus: A Step in the Right Direction
  88. 117 GENE DELIVERY OF DIMETHYLARGININE DIMETHYLAMINOHYDROLASE-1 REDUCES PORTAL PRESSURE IN BILE DUCT-LIGATED RATS
  89. 595 INFLAMMATION UPREGULATES HEPATIC CONNEXIN-43 EXPRESSION IN CIRRHOSIS WHICH DEFINES SUSCEPTIBILITY TO DEVELOPMENT OF ACUTE-ON CHRONIC LIVER FAILURE
  90. 588 ALBUMIN RESTORES RENAL BLOOD FLOW (RBF) AUTOREGULATION IN PATIENTS WITH REFRACTORY ASCITES AND ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) THROUGH STABILIZATION OF ENDOTHELIAL FUNCTION
  91. 1248 ORAL ADMINISTRATION OF NANOPOROUS CARBONS REDUCE SEVERITY OF NON-ALCOHOLIC STEATOHEPATITIS BY MODULATING HEPATIC KUPFFER CELL FUNCTION: A NOVEL THERAPEUTIC APPROACH
  92. 577 ALBUMIN IS CENTRAL IN MEDIATING THE CARDIO-RENAL DYSFUNCTION OF CIRRHOSIS: A STUDY IN ANALBUMINAEMIC RATS
  93. 294 TLR 9 INHIBITION: A NOVEL TARGET OF THERAPY FOR PRIMARY LIVER CANCER
  94. 248 EVIDENCE REFUTING THE TROJAN-HORSE HYPOTHESIS OF BRAIN SWELLING IN ACUTE LIVER FAILURE: L-TYPE GLUTAMINASE IS EXCLUSIVELY NEURONAL
  95. 250 EVALUATION OF HAEMOSTASIS IN ACUTE LIVER FAILURE: A COMPREHENSIVE STUDY USING TRADITIONAL PLASMATIC TESTS AND WHOLE BLOOD THROMBOELASTOGRAPHY
  96. 581 GUT DECONTAMINATION USING NANOPOROUS CARBONS REDUCES PORTAL PRESSURE AND PREVENTS LIVER FAILURE IN BILE-DUCT LIGATED CIRRHOTIC ANIMALS BY REDUCING KUPFFER CELL ACTIVATION
  97. 748 BLOOD LIPIDOMIC PROFILING OF HEPATOCELLULAR CARCINOMA IN HUMAN AND ANIMAL STUDIES IDENTIFIES LYSOPHOSPHATIDYLCHOLINE (24, 0, 0) AS A DISCRIMINATORY BIOMARKER
  98. 680 URINARY TLR4: A NOVEL BIOMARKER TO IDENTIFY PATIENTS WITH ACUTE KIDNEY INJURY IN PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE
  99. 243 A REPRODUCIBLE, CLINICALLY-RELEVANT, INTENSIVELY-MANAGED, PIG MODEL OF ACUTE LIVER FAILURE FOR TESTING OF THERAPIES AIMED TO PROLONG SURVIVAL
  100. 238 EXTRACORPOREAL LIVER SUPPORT USING UCL-ARSENEL REDUCES INFLAMMATION, IMPROVES HAEMODYNAMIC FUNCTION AND INCREASE SURVIVAL TIME IN A PORCINE PARACETAMOL-INDUCED ACUTE LIVER FAILURE MODEL
  101. 293 SELECTIVE GUT DECOMTAMINATION REDUCES HEPATIC EXPRESSION OF TOLL-LIKE RECEPTOR (TLR) 4 AND DEVELOPMENT OF CIRRHOSIS BUT DOES NOT PREVENT DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (HCC)
  102. 586 RENAL NKCC2 TRANSPORTER TRIGGERS ENHANCED URINARY AMMONIA EXCRETION DURING INDUCED HYPERAMMONEMIA: A NOVEL TARGET OF THERAPY FOR HEPATIC ENCEPHALOPATHY?
  103. 91 TOLL LIKE RECEPTOR 4 ANTAGONIST PREVENTS ACETAMINOPHEN INDUCED ACUTE LIVER FAILURE IN MICE: A NOVEL THERAPEUTIC STRATEGY
  104. MODULATION OF TOLL-LIKE RECEPTOR GENES WITH SELECTIVE GUT DECONTAMINATION IN CIRRHOTIC ANIMALS PREVENTS THE DEVELOPMENT OF ACUTE-ON CHRONIC LIVER FAILURE (ACLF)
  105. Systems Biology of the Liver
  106. Dogs with congenital porto-systemic shunting (cPSS) and hepatic encephalopathy have higher serum concentrations of C-reactive protein than asymptomatic dogs with cPSS
  107. The Rise of Glutaminase in End-Stage Liver Diseases
  108. ‘Out-patient’ albumin dialysis for cholestatic patients with intractable pruritus
  109. Extracorporeal Liver Support
  110. Ornithine Phenylacetate: A Novel Strategy for the Treatment of Hepatic Encephalopathy
  111. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study
  112. Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats
  113. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis
  114. Intensive care of the patient with cirrhosis
  115. P17 TIPS outcomes for Budd-Chiari: a single tertiary centre experience
  116. OP09 TIPS outcomes for refractory ascites: a single centre experience
  117. Acute-on-chronic liver failure: from concept to a new syndrome
  118. 611 PROGRESSION OF HEMODYNAMIC CHANGES IN LIVER CIRRHOSIS. A MATHEMATICAL APPROACH
  119. 620 IMMUNOHISTOCHEMICAL CHARACTERIZATION OF ASTROGLIAL IMMUNE RESPONSES IN CIRRHOTIC RATS
  120. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis
  121. Stumbling into encephalopathy: chest trauma in a patient with alcoholic cirrhosis
  122. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies
  123. Management of Hepatic Encephalopathy
  124. Improving Survival in Patients with Decompensated Cirrhosis
  125. Autotaxin spiegelt das Therapieansprechen bei cholestatischem Pruritus wider
  126. SIRS, Bacterial Infections, and Alterations of the Immune System
  127. Acute-on-chronic liver failure: an early biopsy is essential?
  128. Rifaximin in hepatic encephalopathy: More than just a non-absorbable antibiotic?
  129. Role of aquaporin-4 in the development of brain oedema in liver failure
  130. Blood-brain barrier in liver failure: are cracks appearing in the wall?
  131. Short chain fatty acids exchange: Is the cirrhotic, dysfunctional liver still able to clear them?
  132. Intrinsic renal disease in cirrhosis:adding insult to injury
  133. Alcohol takes the toll on immune function
  134. 1184 EXTRACORPOREAL LIVER SUPPORT WITH THE MOLECULAR ADSORBENT RECIRCULATING SYSTEM (MARS) IN PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE (AOCLF). THE RELIEF TRIAL
  135. 523 HEMODYNAMIC EFFECTS OF TEZOSENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH CIRRHOSIS
  136. 537 RESTORATION OF THE L-ARGININE:ADMA RATIO BY L-ARGININE TREATMENT IN BILE DUCT LIGATED RATS RESULTS IN SIGNIFICANT LOWERING OF PORTAL PRESSURE
  137. P.157 “OUT-PATIENT” ALBUMIN DIALYSIS FOR INTRACTABLE ITCH IN CHRONIC CHOLESTATIC LIVER DISEASE IS AN ALTERNATIVE TO LIVER TRANSPLANTATION
  138. F.N.18 NEUTROPHIL PHAGOCYTIC DYSFUNCTION IN STABLE CIRRHOSIS IS INDEPENDENT OF BACTERIAL DNA AND ASSOCIATED WITH INCREASED EXPRESSION OF TLR-4
  139. Albumin: Not Just a Plasma Expander
  140. Infection and inflammation in liver failure: Two sides of the same coin
  141. Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes
  142. Review article: hyperammonaemic and catabolic consequences of upper gastrointestinal bleeding in cirrhosis
  143. 494 THE BIOMARKER ‘DASIMAR’ (DIMETHYLARGININE SCORE AND ISCHAEMIA MODIFIED ALBUMIN RATIO) IS AN EARLY PREDICTOR OF MORTALITY IN PATIENTS WITH ACUTE LIVER FAILURE
  144. 734 TREATMENT WITH INFLIXIMAB INCREASES E-NOS ACTIVITY IN CIRRHOSIS THROUGH MODULATION OF THE DDAH-ADMA PATHWAY
  145. 771 EVIDENCE OF SEVERE NEUTROPHIL DYSFUNCTION IN STABLE CIRRHOSIS USING A NOVEL IN VIVO MODEL OF INFLAMMATION
  146. 773 REDUCTION IN AMMONIA WITH L-ORNITHINE, PHENYLACETATE (OP) BUT NOT ANTI-TNF PREVENTS LPS INDUCED BRAIN EDEMA IN BILE-DUCT LIGATED CIRRHOTIC RATS
  147. 154 THE CONTRIBUTIONS OF DE NOVO ARGININE GENERATION AND ARGINASE ACTIVITY TO WHOLE BODY ARGININE METABOLISM IN ACUTE LIVER FAILURE
  148. Demonstration of dysfunction in neutrophil phagocytosis in stable cirrhosis using a novel in vivo model of inflammation
  149. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure
  150. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality
  151. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats
  152. Role of artificial liver support in hepatic encephalopathy
  153. Interorgan ammonia trafficking in liver disease
  154. Probiotics for patients with liver cirrhosis: Reply
  155. Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis
  156. Protein synthesis is severely diminished following a simulated upper GI bleed in patients with cirrhosis
  157. High prevalence of abnormal alanine and aspartate aminotransferases in a “worried-well” population in the United Kingdom: Rationale for a liver screening program?
  158. Ammonia impairs neutrophil phagocytic function in liver disease
  159. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment
  160. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis
  161. Artificial Liver Support Systems in the Management of Complications of Cirrhosis
  162. Relationship Between Activation of the Sympathetic Nervous System and Renal Blood Flow Autoregulation in Cirrhosis
  163. Towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials
  164. 33 INCREASED NEUTROPHIL TOLL-LIKE-RECEPTOR 2, 4 AND 9 EXPRESSION IN ALCOHOLIC HEPATITIS IS A RESULT OF ITS ACTIVATION RATHER THAN ITS CAUSE
  165. 953 EARLY LIVER BIOPSY IS CRUCIAL FOR ACCURATE DIAGNOSIS OF ALCOHOLIC HEPATITIS AND PROVIDES INDEPENDENT PROGNOSTIC INFORMATION IN PATIENTS WITH DECOMPENSATED ALCOHOLIC LIVER DISEASE
  166. Response to letter by R. Mookerjee and R. Jalan
  167. ADMA correlates with portal pressure in patients with compensated cirrhosis by Vizzutti et al. Eur J Clin Invest 2007; 37: 509-15
  168. Endotoxin measures in patients’ sample: How valid are the results?
  169. Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension
  170. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome
  171. The treatment of hepatic encephalopathy
  172. Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis
  173. Association of reduced extracellular brain ammonia, lactate, and intracranial pressure in pigs with acute liver failure
  174. Protocols and Mechanisms for Remote Ischemic Preconditioning: A Novel Method for Reducing Ischemia Reperfusion Injury
  175. Induction of cerebral hyperemia by ammonia plus endotoxin: Does hyperammonemia unlock the blood–brain barrier?
  176. Increased Gene and Protein Expression of the Novel eNOS Regulatory Protein NOSTRIN and a Variant in Alcoholic Hepatitis
  177. Acute liver failure: liver support therapies
  178. [250] THE EFFECTS OF TEZOSENTAN, AN ENDOTHELIN RECEPTOR ANTAGONIST, ON RENAL FUNCTION IN PATIENTS WITH CIRRHOSIS COMPLICATED BY ASCITES AND HEPATORENAL SYNDROME
  179. [232] ALBUMIN INFUSION FOR SEVERE HYPONATREMIA IN PATIENTS WITH REFRACTORY ASCITES: A RANDOMIZED CLINICAL TRIAL
  180. [212] BRAIN SWELLING AND COMA IN CIRRHOTIC RATS ADMINISTERED ENDOTOXIN IS ASSOCIATED WITH INCREASED PROTEIN NITROSATION
  181. [213] LIPOPOLYSACCHARIDE EXACERBATES BRAIN EDEMA AND PRODUCES COMA IN CIRRHOTIC RATS THROUGH A CYTOTOXIC MECHANISM: AN ELECTRON-MICROSCOPIC STUDY
  182. quantitative tests of liver function
  183. Isoleucine infusion during “simulated” upper gastrointestinal bleeding improves liver and muscle protein synthesis in cirrhotic patients
  184. Role of ammonia and inflammation in minimal hepatic encephalopathy
  185. Ammonia and inflammation in the pathogenesis of hepatic encephalopathy: Pandora's box?
  186. The puzzle of endothelial nitric oxide synthase dysfunction in portal hypertension: The missing piece?
  187. Management of hepatic encephalopathy in patients with cirrhosis
  188. Endotoxemia during liver transplantation
  189. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome
  190. l-Ornithine phenylacetate (OP): A novel treatment for hyperammonemia and hepatic encephalopathy
  191. Endotoxemia produces coma and brain swelling in bile duct ligated rats
  192. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure
  193. Paracetamol: are therapeutic doses entirely safe?
  194. Transjugular intrahepatic portosystemic stent-shunt in the management of gastric and ectopic varices
  195. Acute Liver Failure: a Review
  196. 189 Hepatic inflammation increases portal pressure through inhibition of eNOS activity — Potential mechanisms
  197. Arginine, citrulline, and nitric oxide metabolism in patients with liver failure and the effect of intervention with hypothermia and transplantation
  198. Remote ischaemic preconditioning of the hind limb reduces experimental liver warm ischaemia–reperfusion injury
  199. Systemic and regional haemodynamics in pigs with acute liver failure and the effect of albumin dialysis
  200. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation
  201. Ammonia and Hepatic Encephalopathy: The More Things Change, the More They Remain the Same
  202. Pathophysiological basis of therapy of raised intracranial pressure in acute liver failure
  203. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis
  204. Reply
  205. Treatment of hepatic encephalopathy
  206. Acute liver failure: current management and future prospects
  207. Emerging Indications for Albumin Dialysis
  208. Dispelling myths in the treatment of hepatic encephalopathy
  209. Letter to the Editors
  210. Gc-globulin to predict outcome in acute liver failure: A panacea?
  211. Transjugular Intrahepatic Portosystemic Stent-Shunt
  212. Dispelling myths in the treatment of hepatic encephalopathy
  213. `Nipped in the Budd'
  214. Hypothermia in Acute Liver Failure
  215. A model to study total hepatic ischemia–reperfusion injury
  216. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension
  217. Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow
  218. PROSPECTS FOR EXTRACORPOREAL LIVER SUPPORT
  219. Extracorporeal Albumin Dialysis for Intoxication from Protein-Bound Agents
  220. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid
  221. Albumin dialysis: a new therapeutic strategy for intoxication from protein-bound drugs
  222. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis
  223. Should a biopsy precede liver resection or transplantation for presumed hepatocellular carcinoma when the alfa fetoprotein is normal?
  224. Infliximab and alcoholic hepatitis
  225. Is minimal hepatic encephalopathy completely reversible following liver transplantation?
  226. Binding of bilirubin and bromosulphthalein to albumin: Implications for understanding the pathophysiology of liver failure and its management
  227. The role of the Molecular Adsorbents Recirculating System (MARS) in the management of liver failure
  228. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy
  229. Contractile response of femoral arteries in pigs with acute liver failure
  230. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: A randomized controlled study
  231. 193 Aseptic inflammation independent of its source is important in the development of advanced grades of encephalopathy in alcoholic cirrhosis
  232. Urotensin II: better than somatostatin for portal hypertension?
  233. Reply
  234. Liver failure: basis of benefit of therapy with the molecular adsorbents recirculating system
  235. The molecular pathogenesis of hepatic encephalopathy
  236. Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver
  237. The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis
  238. Correspondence
  239. Moderate hypothermia prevents cerebral hyperemia and increase in intracranial pressure in patients undergoing liver transplantation for acute liver failure
  240. Reversal of severe cholestasis caused by chronic graft-versus-host disease with the MARS liver-support device
  241. Decompensation of chronic stable alcoholic liver disease by severe exfoliative dermatitis
  242. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis
  243. Treatment of Phenytoin Toxicity by the Molecular Adsorbents Recirculating System (MARS)
  244. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis
  245. 167 Pre-primed neutrophil oxidative burst is independent of clinical severity and outcome in patients with severe alcoholic liver disease
  246. 169 Kinetics of binding of non-dialysable substances to albumin: relevance in liver disease
  247. 173 Pathophysiological basis of extracorporeal albumin dialysis with MARS in acute-on-chronic liver failure due to alcohol
  248. 531 Hepatic inflammation is an important modulator of the circulatory disturbances in cirrhosis
  249. 536 Evidence for altered renal blood flow autoregulation in cirrhosis
  250. 652 Remote ischaemic preconditioning of the hind limb improves systemic haemodynamics and reduces reperfusion injury to the liver and lungs
  251. 787 Worsening of cerebral hyperemia in acute liver failure with severe hepatic encephalopathy following terlipressin?
  252. 801 Brain production of pro-inflammatory cytokines in patients with acute liver failure and uncontrolled intracranial hypertension: evidence of disrupted blood brain barrier?
  253. Molecular Adsorbents Recirculating System (MARS) for acute decompensation of chronic liver disease: an early clinical experience
  254. Hypothermia for the management of intracranial hypertension in acute liver failure
  255. Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis
  256. 809 Improvement in cerebral lactate, glutamate and energy metabolism with albumin dialysis in a large animal model of acute liver failure: a microdialysis study
  257. 1083 MARS treatment improves renal function independent of systemic haemodynamics in acute liver failure: a randomized controlled study in a pig model
  258. Terlipressin-induced vasoconstriction reversed with N-acetylcysteine: A case for combined use in hepatorenal syndrome?
  259. Review article: the Molecular Adsorbents Recirculating System (MARS) in liver failure
  260. Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's disease
  261. Liver derived pro-inflammatory cytokines may be important in producing intracranial hypertension in acute liver failure
  262. Primary prophylaxis of variceal hemorrhage: A randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate
  263. Interorgan ammonia metabolism in liver failure
  264. Impact of transjugular intrahepatic portosystemic stent-shunt for secondary prophylaxis of oesophageal variceal haemorrhage: a single-centre study over an 11-year period
  265. Is “Gilbert's” the culprit in indinavir-induced hyperbilirubinemia?
  266. The pathophysiological basis of acute-on-chronic liver failure
  267. Novel spin trap findings demonstrating severe oxidative stress in alcoholic hepatitis
  268. Increased cerebral and peripheral vasodilation, and whole body nitricoxide (NO) production after insertion of a transjugular intrahepatic portosystemic stent-shunt (TIPSS) in patients with cirrhosis
  269. BIO-ARTIFICIAL LIVER SUPPORT FOR ACUTE LIVER FAILURE: SHOULD WE BE USING IT TO TREAT PATIENTS?
  270. Acute-on-Chronic Liver Failure: Pathophysiological Basis of Therapeutic Options
  271. Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy
  272. Hypothermia for the management of intracranial hypertension in acute liver failure
  273. Editorial: Improvement in cerebral perfusion after MARS therapy: Further clues about the pathogenesis of hepatic encephalopathy?
  274. Mars in decompensated Alcoholic Liver Disease with Multi-Organ Failure
  275. Restoration of cerebral blood flow autoregulation and reactivity to carbon dioxide in acute liver failure by moderate hypothermia
  276. The inflammatory basis of intracranial hypertension in acute liver failure
  277. Primary prophylaxis of variceal bleeding in cirrhosis
  278. Altered peripheral vascular responses to vasoactive mediators in patients with pre-ascitic cirrhosis: role of nitric oxide
  279. Study of regional neutrophil chemotaxis in chronic liver diseases (CLD)
  280. Enhanced renal ammonia excretion following volume expansion is mediated through the renin-angiotensin system
  281. Randomised controlled trial of transjugular intra-hepatic portosystemic stent-shunt (TIPSS) versus tipss and variceal band ligation (VBL) in the prevention of variceal rebleeding
  282. Acute changes in cerebral blood flow and metabolism during portasystemic shunting
  283. Vascular hyporesponsiveness in cirrhosis - many facets of a common problem!
  284. MARS: A new treatment for hepatorenal failure
  285. Losartan and renal sodium handling Reply
  286. UK guidelines on the management of variceal haemorrhage in cirrhotic patients
  287. TIPSS 10 years on
  288. Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis
  289. Sodium handling in patients with well compensated cirrhosis is dependent on the severity of liver disease and portal pressure
  290. Hypothermia for fulminant hepatic failure: A cool approach to a burning problem
  291. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis
  292. Double blind randomised study of effect of simulated bleeding onneutrophil chemotaxis in patients with cirrhosis
  293. Interorgan ammonia metabolism in overnight fasted, metabolically stable patients with cirrhosis of the liver
  294. Enhanced renal ammonia production is a major cause of hyperammonemia after a simulated upper gastrointestinal bleed in patients with cirrhosis of the liver
  295. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure
  296. Diagnosis of hepatic encephalopathy: Willin vivo proton MRS play a role?
  297. Indocyanine green clearance reflects reperfusion injury following liver transplantation and is an early predictor of graft function
  298. Simulation of a upper gastrointestinal bleed in patients with cirrhosis of the liver
  299. Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network analysis of virus and clinical factors
  300. Reply to Dr Larsen
  301. Shunt insufficiency after TIPSS
  302. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices
  303. Efficacy of balloon angioplasty, restenting, and parallel shunt insertion for shunt insufficiency after transjugular intrahepatic portosystemic stent-shunt (TIPSS)
  304. Hepatic encephalopathy and ascites
  305. TIPSS trials: Design determines outcome
  306. TIPSS trials: Design determines outcome
  307. Elevation of intracranial pressure following transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage
  308. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices.
  309. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices
  310. Shunt insufficiency after transjugular intrahepatic portosystemic stent-shunt: the whens, whys, hows and what should we do about it?
  311. Primary graft dysfunction after liver transplantation: From pathogenesis to prevention
  312. INFLUENCE OF CYCLIC GUANOSINE MONOPHOSPHATE CHANGES ON HEMODYNAMICS AFTER REPERFUSION IN LIVER TRANSPLANTATION
  313. A comparison between gastric and oesophageal variceal haemorrhage treated with transjugular intrahepatic portosystemic stent shunt (TIPSS)
  314. Transjugular intrahepatic portosystemic stent-shunt (TIPSS) insertion as a prelude to orthotopic liver transplantation in patients with severe portal hypertension
  315. Mechanisms of changes in renal handling of sodium following transjugular intrahepatic portal systemic stent-shunt (TIPSS)
  316. NEUTROPHIL ELASTASE: A DETERMINANT OF ENDOTHELIAL DAMAGE AND REPERFUSION INJURY AFTER LIVER TRANSPLANTATION?
  317. pathogenesis and treatment of chronic hepatic encephalopathy
  318. Differing actions of the acute administration of propranolol and isosorbide-5-mononitrate on the portal circulation
  319. In vivo hepatic magnetic resonance spectroscopy: clinical or research tool?
  320. Longterm follow up of transjugular intrahepatic portosystemic stent shunt (TIPSS) for the treatment of portal hypertension: results in 130 patients.
  321. Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models.
  322. Review article: renal circulatory changes in cirrhosis--pathogenesis and therapeutic prospects.
  323. Prospective evaluation of haematological alterations following the transjugular intrahepatic portosystemic stent-shunt (TIPSS)
  324. Transjugular intrahepatic portosystemic stent-shunt (TIPSS) occlusion and the role of biliary venous fistulae
  325. Risk of intentional reversible thrombosis of transjugular intrahepatic portosystemic shunt.
  326. A prospective evaluation of changes in neuropsychological and liver function tests following transjugular intrahepatic portosystemic stent-shunt
  327. In vitro proton (1H) magnetic resonance spectroscopy of the plasma in cirrhosis and changes following the transjugular intrahepatic portosystemic stentshunt (TIPSS) R. Jalan, Y.L. Chung, D.N.Redhead, *P.C. Hayes, J.D. Bell, R.E. Steiner, MR Unit, Hamme...
  328. Transjugular intrahepatic portasystemic stent—shunt in the treatment of variceal haemorrhage
  329. Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic protosystemic stent-shunt for variceal haemorrhage
  330. The role of duplex and colour Doppler ultrasound in the follow-up evaluation of transjugular intrahepatic portosystemic stent shunt (TIPSS)
  331. Gastric mucosal bleeding time in cirrhosis
  332. A PILOT STUDY OF INDOCYANINE GREEN CLEARANCE AS AN EARLY PREDICTOR OF GRAFT FUNCTION
  333. A PILOT STUDY OF INDOCYANINE GREEN CLEARANCE AS AN EARLY PREDICTOR OF GRAFT FUNCTION
  334. Gastric acid secretion rate and buffer content of the stomach after a rice- and a wheat-based meal in normal subjects and patients with duodenal ulcer.
  335. Testicular torsion in Henoch--Schonlein syndrome.
  336. The role of inflammation in hepatic encephalopathy
  337. Liver Failure and Intracerebral Hypertension